2. Academic Validation
  3. ONT-093 (Ontogen)

ONT-093 (Ontogen)

  • Curr Opin Investig Drugs. 2002 Nov;3(11):1666-71.
Prakash Mistry 1,  Adrian Folkes
Affiliations

Affiliation

  • 1 Xenova Ltd, 957 Buckingham Avenue, Slough, Berkshire, SL1 4NL, UK. prakash_mistry@xenova.co.uk
PMID: 12476971
Abstract

Ontogen is developing ONT-093 (formerly OC-144-093), a P-glycoprotein pump inhibitor, for the potential reversal of multidrug resistance in patients undergoing Cancer chemotherapy. The compound is also being evaluated for its potential enhancement of the oral bioavailability of drugs that are P-glycoprotein substrates requiring either high dosage forms or intravenous administration, and for the potential improvement of central nervous system penetration of P-glycoprotein substrate drugs.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z